UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
|
|
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer |
|
|
|
|
|
|
(Address of principal executive offices, including zip code)
(
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class |
Trading Symbol(s) |
Name of Each Exchange on Which Registered |
|
|
|
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events
On February 24, 2020, Allakos Inc. (the “Company”) issued a press release announcing upcoming presentations related to Eosinophil and Mast Cell-Driven Diseases at the 2020 AAAAI Annual Meeting. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
|
Description |
|
|
|
|
|
99.1 |
|
|
|
|
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Allakos Inc. |
|
|
|
|
|
|
|
Date: February 24, 2020 |
|
By: |
/s/ Robert Alexander |
|
|
|
|
Robert Alexander |
|
|
|
|
Chief Executive Officer |
2
Exhibit 99.1
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 AAAAI Annual Meeting
REDWOOD CITY, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced that the Company will present clinical and preclinical results in a number of diseases where mast cells and/or eosinophils have been shown to play a role in disease pathology. The presentations will take place at the 2020 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting being held in Philadelphia, Pa. from March 13 to 16, 2020.
Oral Presentations:
|
Title (Abstract):
Presenter: Session/Time: |
AK002, an Anti-Siglec-8 Antibody, Depletes Tissue Eosinophils and Improves Dysphagia Symptoms in Patients with Eosinophilic Esophagitis (#539) Ikuo Hirano, MD Advances in Eosinophilic Esophagitis/March 15, 2:00-3:15 pm |
|
Title (Abstract):
Presenter: Session/Time: |
Clinical Activity of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Treatment-Refractory Chronic Urticaria (#779) Sabine Altrichter, MD Atopic Dermatitis with a Side of Urticaria/March 16, 2:00-3:15 pm |
Featured Poster Presentations:
|
Title (Abstract):
Presenter: Session/Time: |
AK002, an Anti-Siglec-8 Antibody, Suppresses Acute IL-33-induced Neutrophil Infiltration and Attenuates Tissue Damage in a Chronic Experimental COPD Model Through Mast Cell Inhibition (#568) Julia Schanin, PhD New Insights in Asthma Genomics and Cell Signaling/March 15, 4:45-6:15 pm |
|
Title (Abstract):
Presenter: Session/Time: |
Phase 1b Study of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Patients with Severe Allergic Conjunctivitis (KRONOS Study) (#593) Terry Levine, MD Headlines in Immunotherapy, Rhinitis, Sinusitis and Ocular Disease/March 15, 4:45-6:15 pm |
Poster Presentations:
|
Title (Abstract):
Presenter: Session/Time: |
Atopic Dermatitis Skin Biopsies Have High Numbers of Activated Mast Cells that are Inhibited by AK002 after Stimulation Ex Vivo (#637) Amol P. Kamboj, MD Atopic Dermatitis/March 16, 9:45-10:45 am |
|
Title (Abstract):
Presenter: Session/Time: |
EoE Biopsies have Elevated and Activated Mast Cells that Produce Cytokines and Chemokines that Drive Disease Pathogenesis (#129) Bradford A. Youngblood, PhD Pathogenesis and Treatment of Eosinophilic Esophagitis/March 14, 9:45-10:45 am |
|
Presenter: Session/Time: |
A Longitudinal, Population-Based Study of the Difficult Journey to Diagnosis Endured by Patients with Eosinophilic Gastritis and Eosinophilic Gastroenteritis (#121) Mirna Chehade, MD MPH Diagnosis of Eosinophilic Esophagitis/March 14, 9:45-10:45 am |
Following the presentations, the posters will be available on the Allakos website.
About Allakos
Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, antolimab (AK002), targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Antolimab (AK002) has been shown to inhibit mast cells and deplete eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Antolimab (AK002) has been tested in five clinical studies. In these studies, antolimab (AK002) eliminated blood eosinophils and improved disease symptoms in patients with eosinophilic gastritis and/or eosinophilic gastroenteritis, eosinophilic esophagitis, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. For more information, please visit the Company's website at www.allakos.com.
###
Source: Allakos Inc.
|
Investor Contact: |
|
Media Contact: |
|
Adam Tomasi, President and COO |
|
Denise Powell |
|
ir@allakos.com |
|
denise@redhousecomms.com |